Notice NOT-EB-24-004 from the NIH Guide for Grants and Contracts

£42,577 - £47,039. Pro-rata salary for job share: Animal and Plant Health Agency: At the Animal and Plant Health Agency, we safeguard animal and plant health for the benefit of people, the environment and the economy. New Haw, South East England, KT15 3NB

Notice NOT-AT-24-029 from the NIH Guide for Grants and Contracts

Notice NOT-CA-24-025 from the NIH Guide for Grants and Contracts

Notice NOT-OD-24-055 from the NIH Guide for Grants and Contracts

Notice NOT-AT-24-032 from the NIH Guide for Grants and Contracts

£35,857 - £38,551 A Civil Service Pension with an average employer contribution of 27%.: Animal and Plant Health Agency: The Animal and Plant Health Agency (APHA) is an executive agency of the Department for Environment,..... Weybridge, Surrey

Funding Opportunity RFA-NR-24-004 from the NIH Guide for Grants and Contracts. The Transformative Research to Address Health Disparities and Advance Health Equity initiative is soliciting applications to support unusually innovative intervention research addressing social determinants of health (SDOH) which, if successful, would have a major impact on preventing, reducing, or eliminating health disparities and advancing health equity. Projects should clearly demonstrate, based on the strength of the logic, a compelling potential to produce a major impact on advancing NIHs commitment to addressing SDOH to accelerate progress in improving health for all. Preliminary data are not required for this initiative.

Notice NOT-CA-24-026 from the NIH Guide for Grants and Contracts

Myriad Genetics: Software Engineer III - Bioinformatics (South SF, CA, Hybrid, USA) We need a Software Engineer to help Myriad Genetics, Inc. deliver innovative pro... South San Francisco, California

40% Implements appropriate data science techniques under the guidance of other data scientists, statisticians, and/or other researchers to find data patterns… $50,000 a year
From University of Wisconsin–Madison - Mon, 22 Jan 2024 19:25:39 GMT - View all Madison, WI jobs

Funding Opportunity PAR-24-096 from the NIH Guide for Grants and Contracts. The purpose of this Program Announcement (PAR) is to enable clinical validation of strong candidate biomarkers for neurological diseases and conditions. Specifically, the goal of this PAR is to enable the rigorous validation of biomarker measurements within the clinical population of interest to establish the positive and negative predictive values of the candidate biomarker consistent with FDA guidelines. This PAR assumes that 1) a candidate biomarker has already been identified, 2) detection method technology has already been developed and analytically validated, and 3) the research and/or clinical need and potential context of use has been identified.

Funding Opportunity PAR-24-095 from the NIH Guide for Grants and Contracts. (Reissue PAR-21-056) The purpose of this Program Announcement (PAR) is to enable analytical validation of strong candidate biomarkers for neurological diseases and conditions. Specifically, the goal of this PAR is to enable the rigorous validation of analytical methods for biomarker measurements, including evaluation of the detection method, its performance characteristics, and the optimal conditions that will generate reproducibility and accuracy consistent with FDA guidelines. This PAR assumes that 1) a candidate biomarker has already been identified, 2) detection method technology has already been developed, and 3) the research and/or clinical need and potential context of use has been identified.

Notice NOT-AG-23-076 from the NIH Guide for Grants and Contracts

Notice NOT-DC-24-021 from the NIH Guide for Grants and Contracts

Notice NOT-AT-24-031 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-24-129 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to provide continuing support for specific pathogen-free (SPF) macaque colonies previously funded under the auspices of PAR-21-089 and PAR-18-669 that support Human Immunodeficiency Virus (HIV)/Acquired Immunodeficiency Syndrome (AIDS) research. Breeding colonies are essential to sustain appropriate SPF macaques for research related to HIV/AIDS. Pedigree SPF macaques are free of certain viruses, which may confound the results of HIV/AIDS-related investigations or present a risk to the personnel who care for the animals. The SPF macaques are genetically characterized for major histocompatibility complex (MHC) class I types, because MHC class I genotypes have large effects on macaque immune responses to Simian Immunodeficiency Virus (SIV) that can induce AIDS in nonhuman primates (NHPs) and on human immune responses to HIV.

Funding Opportunity PAR-24-113 from the NIH Guide for Grants and Contracts. The purpose of the International Research Scientist Development Award (IRSDA) is to provide support and protected time (three to five years) to advanced postdoctoral U.S. research scientists and recently-appointed U.S. junior faculty (applicants must be at least two years beyond conferral of doctoral degree) for an intensive, mentored research career development experience in a low- or middle-income country (LMIC), as defined by the World Bank (http://data.worldbank.org/about/country-classifications/country-and-lending-groups, including "low-income," "lower-middle-income," and "upper-middle-income" countries) leading to an independently-funded research career focused on global health. This Funding Opportunity Announcement (FOA) invites applications from postdoctoral research scientists and junior faculty from any health-related discipline who propose career development activities and a research project that is relevant to the health priorities of the LMIC under the mentorship of LMIC and U.S. mentors.

Funding Opportunity PAR-24-097 from the NIH Guide for Grants and Contracts. (Reissue PAR-21-058). The purpose of this Program Announcement (PAR) is to enable clinical validation of strong candidate biomarkers for neurological diseases and conditions. Specifically, the goal of this PAR is to enable the rigorous validation of biomarker measurements within the clinical population of interest to establish the positive and negative predictive values of the candidate biomarker consistent with FDA guidelines. This PAR assumes that 1) a candidate biomarker has already been identified, 2) detection method technology has already been developed and analytically validated, and 3) the research and/or clinical need and potential context of use has been identified.

Funding Opportunity PAR-24-098 from the NIH Guide for Grants and Contracts. (Reissue PAR-21-057) The purpose of this Program Announcement (PAR) is to enable analytical validation of strong candidate biomarkers for neurological diseases and conditions. Specifically, the goal of this PAR is to enable the rigorous validation of analytical methods for biomarker measurements, including evaluation of the detection method, its performance characteristics, and the optimal conditions that will generate reproducibility and accuracy consistent with FDA guidelines. This PAR assumes that 1) a candidate biomarker has already been identified, 2) detection method technology has already been developed, and 3) the research and/or clinical need and potential context of use has been identified.